Abstract
The present invention provides a bladder cancer biomarker and its testing method. The biomarker contains at least one selected from of a group consisting of apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), existed in the urine specimen of a testee. The expression intensity of the biomarker can assist in diagnosing bladder cancer and determining invasion level of cancer cells so as to facilitate understanding of the conditions of patients with bladder cancer, thereby arranging an optimized treatment to achieve the best therapeutic effect.
Translated title of the contribution | Bladder cancer biomarker and its testing method |
---|---|
Original language | Chinese (Traditional) |
Patent number | I390204 |
IPC | G01N 33/574(2006.01); G01N 33/68(2006.01) |
State | Published - 21 03 2013 |
Bibliographical note
公開公告號: I390204Announcement ID: I390204